Aligos Therapeutics, Inc. (ALGS)
Automate Your Wheel Strategy on ALGS
With Tiblio's Option Bot, you can configure your own wheel strategy including ALGS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ALGS
- Rev/Share 0.3889
- Book/Share 13.8485
- PB 0.5156
- Debt/Equity 0.0676
- CurrentRatio 7.5578
- ROIC -0.6427
- MktCap 43659672.0
- FreeCF/Share -9.3965
- PFCF -0.5526
- PE -1.1272
- Debt/Assets 0.0522
- DivYield 0
- ROE -1.0402
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ALGS | H.C. Wainwright | -- | Buy | -- | $75 | Aug. 19, 2024 |
News
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: May 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase an aggregate of 26,000 shares of the Company's stock (the “Inducement Grant”) to a newly hired employee on May 13, 2025 (the “Grant Date”), in connection with the commencement of employment.
Read More
Aligos Therapeutics Presents Positive Data at the EASL Congress 2025
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from eight presentations at the European Association for the Study of the Liver (EASL) Congress 2025, being held May 7 – 10, 2025 in Amsterdam, Netherlands.
Read More
Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Misses Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $2.11 per share versus the Zacks Consensus Estimate of a loss of $2.80. This compares to loss of $5.50 per share a year ago.
Read More
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the first quarter 2025.
Read More
Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025
Published: April 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company's first quarter 2025 financial results on Tuesday, May 6, 2025, before the open of the U.S. financial markets.
Read More
Aligos Therapeutics Presents Positive Data at APASL 2025
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from three oral presentations at the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL) 2025, being held March 26 - 30, 2025 in Beijing, China.
Read More
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates
Published: March 10, 2025 by: Zacks Investment Research
Sentiment: Negative
Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $3.41 per share versus the Zacks Consensus Estimate of a loss of $1.91. This compares to loss of $5.50 per share a year ago.
Read More
Aligos Therapeutics Announces $105 Million Private Placement Financing
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Proceeds expected to fund the start of the ALG-000184 Phase 2 clinical study Funding expected to extend cash runway into the second half of 2026 SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $105 million, before deducting placement agents' fees and other expenses.
Read More
About Aligos Therapeutics, Inc. (ALGS)
- IPO Date 2020-10-16
- Website https://www.aligos.com
- Industry Biotechnology
- CEO Lawrence M. Blatt MBA,
- Employees 70